CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis

CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis

Source: 
BioSpace
snippet: 

In January, San Diego-based Poseida Therapeutics eyed a potential $115 million initial public offering to support the development of its CAR-T medicines to treat various blood and solid tumors. The company seems to have scrapped that and instead raised $142 million, with significant support from Novartis.